J Goodwin to Diphosphonates
This is a "connection" page, showing publications J Goodwin has written about Diphosphonates.
Connection Strength
2.305
-
Goodwin JS. In Reply-Bisphosphonates and Osteonecrosis of the Jaw. Mayo Clin Proc. 2017 07; 92(7):1167.
Score: 0.538
-
Goodwin JS, Zhou J, Kuo YF, Baillargeon J. Risk of Jaw Osteonecrosis After Intravenous Bisphosphonates in Cancer Patients and Patients Without Cancer. Mayo Clin Proc. 2017 Jan; 92(1):106-113.
Score: 0.515
-
Baillargeon J, Kuo YF, Lin YL, Wilkinson GS, Goodwin JS. Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates. Ann Pharmacother. 2011 Oct; 45(10):1199-206.
Score: 0.361
-
Wilkinson GS, Baillargeon J, Kuo YF, Freeman JL, Goodwin JS. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol. 2010 Nov 20; 28(33):4898-905.
Score: 0.338
-
Giordano SH, Fang S, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use of intravenous bisphosphonates in older women with breast cancer. Oncologist. 2008 May; 13(5):494-502.
Score: 0.285
-
Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst. 2007 Jul 04; 99(13):1016-24.
Score: 0.269